Please wait while we load the requested 10-K report or click the link below:
Chief Financial Officer
Vice President, Corporate Communications
PROVIDES FINANCIAL EXPECTATIONS FOR FISCAL 2009
of $167 million for Fiscal 2008
Positive Cash Flows from Operations in Fiscal 2009
|§||Record GAAP net income of $167.0 million.|
|§||Manufacturing and royalty revenues from RISPERDAL® CONSTA® of $124.6 million. Worldwide sales of RISPERDAL CONSTA by Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. (Janssen - Cilag outside the U.S.) were approximately $1.2 billion in fiscal 2008, a 27 percent increase over sales of RISPERDAL CONSTA in fiscal 2007.|
|§||Repurchase of 7.0 million shares of common stock for $93.4 million as part of an ongoing stock repurchase program.|
|§||Strong financial position, with cash and total investments of $460.4 million.|
The following information was filed by Alkermes Inc on Thursday, May 22, 2008 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one year to another to evaluate Alkermes Inc's financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Alkermes Inc.